1502
www.klinickafarmakologie.cz340804001076513320121425327329234035839843647950254457164568672477179183988990895196610061045
/26908040010732
Klin276780400107446583131
Farmakol2918804001074279105179220258305325
Farm.3263804001074178105179195
2026;40(1):25-333478804001074487128171186229275299339357371415460487528569
/40928040010732
KLINICKÁ4170804001074588109168189242288346
FARMAKOLOGIE4538804001074191138210265312372415474533554598
A51578040010753
FARMACIE5231804001074292139211266317337381
3356558020012657113
HLAVNÍ4945200012671127198263336370
TÉMA5337200012657114204274
Biologická37423600106345192124163203220255290332
léčba40903600106296196132172
astmatu427836001063872104158198226268
na456236001063979
konci465636001063473114149167
první483836001063368106148165
čtvrtiny501936001063266106142173191232269
21.53033600106336477
století539436001063163102134166200217
29.343630085367285
Bystroň442630083356794118139176215
J.6706300832437
Účinnost720630083447590128166204231254
léčby988630083155082121152
anti-IgE1154630083327091107129145184218
monoklonální13856300835796134173203220258296329344382397
protilátkou17956300833961981201351501832043437300832967104
nejen460730083377287122159
u63273008337
těžkého682730083215584114148186224
alergického918730083324782103141156187217251289327
astmatu1258730083315880138170192229
(problémy,1500730083195879116156171206263294303
skutečnost,18167300832656941161491823438300833876103126139
naděje).4978300833870109144159194211222
Alergie.734830083415792113151166201213
2011;13:264-267.9628300833569100128136166196208243277313336367401433440
30.343930085357084
Ledford4379300833163101119154175211
D,6589300834554
Busse723930083347095120153
WW,88793008356115123
Trzaskoma1020930083324877109134162197253284
B,13159300833446
et13719300833354
al.1436930083314556
A150393008340
randomized1554930083205187124161217230258290328
multicenter189293008357921063431030083223667100138159192212
study5701030083264986124156
evaluating7411030083346598112149181202216253292
Xolair10481030083387489120135155
persistence12181030083397494121135160183216253285318
of155110300833756
response16221030083205480118156194220254
after18911030083325074107128
long-term3431130083155290128150172205225283
therapy.6401130083225993114146185215224
J878113008325
Allergy9161130083415671105125163194
Clin11241130083405469106
Immunol.124411300831572129166203241256268
2017;140:162-169.15261130083346899127136166196231244273303336356386416449460
31.3431230085377285
Krčmová4491230083365992152192225259
I,73012300831529
Novosad78112300834685119158186220261
J,106412300832538
Malá112312300835690107140
E,128512300833347
et135412300833558
al.14341230083334963
Small,151912300833393127143159172
prospective,1713123008339621011291692062412662823431330083326779
observational,44313300833777104140161196230252267306345377393406
pilot8701330083385470108131
study10211330083275089128161
in120213300831553
severe12761330083276295129151185
asthmatic14821330083325983121180213235250283
patients17851330083397395110145184206234
after3431430083335379115138
omalizumab50614300833899133150166196237297331372
treatment9031430083234581115138198235275298
discontinuation.12261430083405684118156197220236276315349372389429469483
Clin17351430083415773113
Ther.187314300833475112134146
2018;40:1942-1953.34315300833468100131143178214227257287323355376406437471504516
32.3431630085367186
Labrador-Horrillo44916300833165104126159198236257277323361383405420436451489
M,95716300835568
Ferrer10451630083326788109144165
M.123016300835468
Profile13181630083355593110127143177
of151516300833757
omalizumab159116300833896128144159188226284316355
in196616300831553
the3431730083226096
treatment4591730083224478110132191226265286
of76617300833757
chronic8441730083316991128167182215
spontaneous107917300832666105144165199237272311350376
urticaria.1476173008337598499131164186202234247
Drug174417300834668106146
Des191017300834681109
Devel34318300834581113147163
Ther.52118300833372107128139
2015;9:4909-4915.67518300833468100130141176189224257293328351388421453483495
33.3431930085367186
Wood45019300835894133173
RA,6441930083357893
Togias75719300833367107122154181
A,95919300834155
Sicherer10351930083324779117153174208230
SH,12851930083337790
et139519300833457
al.14721930083324861
Omalizumab1554193008347105138154169198236294327366
for19411930083185678
the3432030083226299
Treatment4642030083335287120143204240280303
of78920300833858
Multiple87020300835695111135151192209245
Food113720300833473113154
Allergies.13132030083435975111134174190226254268
N1604203008346
Engl167220300833373113130
J1824203008325
Med.187120300835693134148
2024;390:889-99.34321300833468101133145180213249262297332366390425460471
34.3432230085367388
Wenzel45122300835791129158192208
SE.6792230083336578
Eosinophils7772230083337097112150188228266281296322
in112022300831452
Asthma11932230083416992130188220
—1433223008370
Closing15242230083405593120135172211
the17562230083216095
Loop187122300833169107147
or34323300833759
Opening41723300834787122161176214253
the6852330083226095
Door?79523300834584123144167
N977233008345
Engl103723300833370109125
J1177233008324
Med.121723300835489129142
2009;360:1026-1028.137423300833468104140152187222257270300332365398422452484517551564
35.3432430085367186
Pavord4452430083356799136158196
ID,6572430083156172
Korn7452430083357394133
S,89424300833346
Howarth95624300834483134166188212250
P,122324300833540
et127924300833456
al.13522430083324760
Mepolizumab142924300835489128167183198227265323356395
for18402430083195678
severe1934243008326613432530083326687122
eosinophilic48525300833473100115153191231269284300315347
asthma8522530083325982120178211
(DREAM):108325300831965101135178233252264
A1367253008341
multicentre,142925300835795110133148180214252274295329341
double-179125300833876114154170205228
-blind,343263008321617792130169181
placebo-controlled5402630083385486119152192230254287324363384406443459474509548
trial.1104263008321435890106119
Lancet.123826300833165103135169191204
2012;380:651-659.145826300833468100130142177211247260295329360379416450482493
36.3432730085367288
Ortega4512730083476994128167200
HG,67127300834489102
Liu7942730083314784
MC,89927300835495108
Pavord10282730083356798136158196
ID,12442730083156172
et133627300833557
al.14132730083324861
Mepolizumab149427300835590129168184199228267325357396
Treatment1911273008332508434328300833254112147185206
in56528300831553
Patients6342830083356789104139177198226
with8762830083516689127
Severe101928300833368100134155189
Eosinophilic12252830083327096111149187227265280296311343
Asthma.15842830083416892130188220233
N1833283008345
Engl189428300833371110125
J343293008324
Med.38229300835590130143
2014;371:1198-1207.54029300833468100131143178210243251281309339374396427457491524530
37.3433030085367180
Bel4433030083357186
EH,5503030083337790
Wenzel66130300835790129158192208
SE,8903030083326578
Thompson98830300833372111169209236274313
PJ,13213030083355567
et140830300833557
al.14853030083324861
Oral156630300834769103118
glucocorticoid-sparing170530300833853911231601932302522762923433130083316884122145172211244265280318357
effect7133130083345473107140164
of89031300833757
mepolizumab96031300835792132170186201230269326359398
in137131300831553
eosinophilic14373130083347399114152190230268283299314346
asthma.17963130083315881119177210223
N343323008345
Engl40332300833370109125
J543323008324
Med.58332300835489129142
2014;371:1189-1197.74032300833468100131143178210243251281309340374397428456486519525
38.3433330085367288
Chupp45033300834078115154194
GL,6633330083447689
Bradford7723330083355689128148185207245
ES,10363330083336779
Albers11343330083415796131152180
FC,13333330083327285
et143733300833457
al.15133330083314760
Efficacy1592333008332506886118151183216
of182733300833857
mepolizumab1903333008357923433430083397793108137176234266305
add-on66734300833170109132171210
therapy8953430083226095116149188220
on113334300833776
health-related122734300833873105120142181203225259275307329362402
quality164734300833876108124139161195
of186034300833757
life1935343008315304984
and34335300833271110
markers47435300835891113144179200228
of72335300833857
asthma8013530083325983122180213
control103535300833269108130152190206
in126235300831554
severe13373530083266294129151186
eosinophilic154335300833574101116155194234273289304320352
asthma1916353008332598334336300833896128
(MUSCA):49136300831973117149190232251263
a775363008332
randomised,8273630083215492131169228243269304344357
double-blind,120436300833877115154170205228268284299337376389
placebo-controlled,16143630083385487119153192231254288325364385343373008321587489124163176
parallel-group,5333730083387192125141156191206228269290327365405416
multicentre,96337300835795110133148180214252273295329341
phase131737300833977110136171
3b150237300833473
trial.1588373008322435991106119
Lancet172137300833165103135168191
Respir1925373008336713433830083266581102
Med.46038300835490129142
2017;5:390-400.61838300833468100129139174185220253289313349385422434
39.3433930085357083
Han43739300834375112
JK,5613930083245872
Bachert6453930083356799136170190214
C,87139300833952
Fokkens9353930083326898128162199224
W,117139300835766
et124939300833355
al.13163930083314658
Mepolizumab138639300835488126164180194222259316347386
for17843930083185475
chronic187139300833168881253434030083375283
rhinosinusitis4394030083205873110148174189226263289303325340366
with8174030083506688125
nasal9554030083376995127142
polyps11104030083387692123163189
(SYNAPSE):13114030083195085131171206239271290302
a1625403008332
randomised,16694030083205390129166224239264299338350
double-blind,34341300833876114154169204227267283298336375388
placebo-controlled,7514130083385486118152191230254287324363384406443459474509548561
phase133241300833877109136171
31522413008334
trial.1576413008322435991106119
Lancet171541300833165103135168191
Respir1925413008336713434230083266581102
Med.46042300835490129142
2021;9:1141-1153.61842300833468101132140176189219246277308326357385415448460
40.3434330085367489
Roufosse44843300833574112131169195222257
F,72243300833238
Kahn77743300833569107145
J-E,939433008324478194
Rothenberg10504330083357496134169207246282303341
ME,140843300835488101
et152643300833456
al.15994330083324760
Efficacy1676433008333506886118151183217
and191043300833169108
safety3434430083276282118141177
of54444300833858
mepolizumab62644300835996137178195211241281341375416
in106644300831555
hypereosinophilic114544300833870112149172208248276292332372413453470486502535
syndrome:170444300832761102143165204265301315
A343453008341
phase40545300833978110137172
III,598453008315304659
randomized,6774530083215493132171229245274308348361
placebo-controlled10594530083395587120154193232256290327366388409447463478514553
trial.1633453008322445992107120
J1774453008324
Allergy18194530083415772107129167200
Clin3434630083405570108
Immunol.46646300831573131168206245261273
2020;146:1397-1405.75546300833468101135148178209245258287317350383402433464500534546
41.3434730085366981
Wechsler43847300835791123161188203238259
ME,71147300835588101
Akuthota82747300834171109132170208230263
P,110447300833540
Jayne11584730083255788126161
D,133447300834556
et140447300833457
al.14754730083324760
Mepolizumab155047300835489129167183198227266323356395
or196047300833758
Placebo3434830083355082114148187226
for5824830083185677
Eosinophilic6724830083337097112150188227266281296311343
Granulomatosis10284830083446598136174189227285318339376403418444
with14854830083506688126
Polyangiitis.16244830083367288120153191230245260282298324337
N1974483008345
Engl34349300833370109125
J483493008324
Med.52349300835489129142
2017;376:1921-1932.68049300833468100129139174206238251280311344375394425455488520533
42.3435030085367086
Moiseev44150300835492108133168203235
S,68950300833345
Zagvozdkina74750300833870109142179207245275291329361
E,112050300833346
Kazarina11795030083346897130151167204236
V,142850300833644
et148550300833456
al.15545030083324760
Mepolizumab162650300835589128167183198226264322354393
in34351300831552
patients4085130083397193108143181202229
with6505130083516688126
eosinophilic7895130083347399114151190229267282297312344
granulomatosis11465130083385991129167182220278310331368395409435
with15945130083516688126
polyangiitis.17335130083397793125157195234249264343523008322376377
J435523008324
Allergy4745230083415772107128166198
Clin6885230083395570108
Immunol.81152300831572130168206244260273
2019;144:621.109952300833469100131143173205241254289322354363
43.3435330085377388
Bettiol4525330083367295120136175192
A,66553300834257
Urban74353300834566107141180
ML,94453300835689103
Dagna106853300834679120159192
L,128153300833246
et134953300833457
al.14285330083324861
Mepolizumab151153300835591132172188204234273332366406
for19385330083195880
Eosinophilic3435430083337299115154193234273289305320353
Granulomatosis71854300834467101140178194233293327349387415430457
With11965430083597699138
Polyangiitis:13555430083367491123157196236252268291307334347
A1723543008342
European1786543008334719313117220934355300833372
Multicenter43655300835695111134150184218258280315337
Observational79555300834889117153175211245267283323362396412
Study.12285530083345695135168179
Arthritis14285530083426490130151168191207234
Rheumatol.168455300833676112151210244266305321335
2022;74:295-306.34356300833468101136148181212224259293327349381416452465
44.3435730085367490
Orecchia45257300834769103136166204219251
M,72457300835467
Welbeck81257300835790106145180213243
K,107557300833550
Dexter114557300834580112136170191
J,135657300832436
et141357300833456
al.14895730083324760
Generation156957300834479117152174207228244282320
and190957300833270109
preclinical3435830083396094127142157195210242275290
assessment6535830083325985120147174231266304326
of99958300833757
depemokimab,107558300833973113148206244275291349381421433
an152858300833169
enhanced161758300833472110143181213247286
IL-51923583008315476296
antagonist3435930083327091124163201240255281304
monoclonal66259300835896135173206221259297330345
antibody.10225930083327092107146185225257267
Heliyon.13045930083447995110141179217231
2026;12:e44247.155059300833468101135147177207220254290327360392424430
45.3436030085367185
Singh4416030083324784123161
D,61460300834656
Fuhr68360300833268106127
R,82260300833649
Bird8846030083355071109
NP,10066030083448084
et110360300833356
al.11716030083324760
A1243603008341
Phase129760300833572104130165
11475603008334
study15216030083264987126157
of169160300833756
the17606030083215994
long-18676030083145290129152
-acting3436130083205283106121158196
anti-IL-55516130083316889103125141171186219
monoclonal78261300835693131168200214252289320335
antibody11296130083316889104142179218249
GSK3511294139061300834375108144176206233262295330
in173261300831451
patients17956130083387091105139176197224
with3436230083516689127
asthma.4856230083325882120178210223
Br72462300833556
J796623008324
Clin8356230083405570108
Pharmacol.95862300833573105126185217249286302315
2022;88:702-712.128862300833569101136149184219231265298331351382415445457
46.3436330085367489
Jackson4496330083245688119147186224
DJ,6906330083466880
Wechsler78763300835891123161188203238259
ME,106363300835588101
Jackson11816330083245689119148186224
DJ,14226330083466880
et151963300833456
al.15936330083314760
Twice-Yearly16706330083327995127161184217248279301316348
Depemokimab34364300834581120155213252282299356389428
in78764300831553
Severe85664300833368100135156190
Asthma10626430083416992131188221
with12996430083516689127
an144264300833270
Eosinophilic15296430083327096111149187227266281296311343
Phenotype.1888643008335731083436530083387698131171207219
N577653008345
Engl63765300833371110125
J777653008325
Med.81765300835489129142
2024;391:2337-2349.97465300833569102133145180214246254289324357389408439473509542553
47.3436630085367080
Nolasco44366300834584100132159191229
S,69266300833346
Crimi7586630083406277135151
C.92966300834054
Depemokimab,100466300834581120156214253284300358391431443
the14676630083226196
first1583663008317355683107
ultra-long-1710663008338537697130153170208247286309
-acting3436730083215385109125163202
anti-IL-55586730083327091107129145177192226
monoclonal79867300835796134172205220258297329345
antibody11566730083327091107146185224256
for14266730083185677
severe15176730083266193127149183
eosinophilic1713673008334731001141521912302692843436830083153062
asthma.4206830083325882120178210223
Med.65968300835489129142
2024;5:1452-1455.81668300833468101133145180191221252285318338369400433465477
48.3436930085367490
Kolbeck4506930083357288127163195226
R,69369300833549
Kozhich76069300833472100139154186224
A,100169300834155
Koike10736930083357388118152
M,124369300835468
et132869300833456
al.14026930083314760
MEDI-563,147969300835588133149172206240274286
a1782693008332
humanized1831693008338751331653437030083375382116155
anti-IL-55117030083327091107129145177192226
receptor7507030083215587121160182219241
α1004703008337
mAb105470300835799138
with12057030083506688127
enhanced134570300833472110142180212246285
antibody-dependent1643703008332709110714618422425627831835334371300833974112151186224246
cell-mediated608713008331658196118177212251267299320354394
cytotoxicity10217130083316589126148185216231263278301334
function.13757130083185795127151166204243256
J1650713008324
Allergy16947130083415671106127166198
Clin19117130083405570108
Immunol.34372300831573130168206244260273
2010;125:1344-1353.63172300833569101132145175205240251280310346383406437467499533545
49.2138630085366981
Laviolette2229630083316392106143157190210233265
M,25036300835466
Gossage25796300834380105130161198231
DL,2820630083457587
Gauvreau29176300834374110141161193223259
G,31856300834456
et32506300833454
al.3314630083324557
Effects3380630083335069101132154180
of35706300833755
benralizumab36346300833972108128159213873008315285693149180218
on23707300833774
airway2458730083324665117149178
eosinophils2650730083347197110147183222259272286311
in29757300831451
asthmatic3040730083315778115172202223237267
patients3321730083397091105138175195221
with3556730083506586122
sputum3692730083266410121388300832258115
eosinophilia.2265830083347197110147184222259272286300330342
J262083008324
Allergy2657830083415568102122158189
Clin2859830083395367103
Immunol.29758300831571127164200237252263
2013;132:1086-1096.3251830083346797125135164193224235263293327361384413443477511523
50.2138930085367287
Nowak22409300834583134167197
RM,24529300833591104
Parker2571930083356788118153174
JM,2759930083258093
Silverman286793008332476295129150208241279
RA,3161930083357892
et32689300833456
al.3339930083314760
A341393008341
randomized3469930083215492131169227242271306345
trial2138103008322446093108
of226710300833858
benralizumab,234610300833975114136170185201230269328361401414
an278110300833271
antiinterleukin28731030083327193108124163185219241257293331362379417
53311103008335
receptor33671030083215689123163186224246
α3634103008338
monoclonal369310300835897213811300833877111126165205238254
antibody,24131130083327193109148188229261271
after27051130083335278112134
acute286011300833265104127162
asthma.30431130083325983122181214228
Am3292113008341100
J3413113008325
Emerg345911300833392128150188
Med.366911300835591131145
2015;33:14-20.213812300833468100130141176209220250281304335369382
51.21381330085356879
Bleecker22281330083354983117148177210230
ER,24691330083326679
FitzGerald2559133008332466796140174194226240278
JM,28471330083247890
Chanez294813300833976107143177205
P,316413300833538
et321313300833455
al.32791330083314557
Efficacy3347133008332496684115146177209
and356713300833268106
safety36841330083265775108213814300832254
of220414300833756
benralizumab227114300833973111131163178192220258315346384
for26671430083185576
patients27541430083397192106140178198225
with29911430083506587124
severe31261430083266192126146179
asthma33171430083315780117174205
uncontrolled35341430083377410514117920022025721381530083152962100
with22491530083506586123
high-dosage23831530083375189125147186223248280318351
inhaled27451530083155188119133167205
corticosteroids29611530083316787110125155191217239271291327341379404
and337615300833168106
long-acting34931530083145188126147178209232246283321
β2-agonists21381630083387190122160198236250275298325
(SIROCCO):2481163008319506499146186224269286297
a2796163008332
randomised,28461630083215391129167224239264298337349
multicentre,321316300835895109131146177210247268289322333
placebo-35651630083385485117150188226249
-controlled21381730083215490128149169206221235270308
phase246017300833977108134169
32643173008334
trial.2691173008321425788103115
Lancet.282017300833164101133166188200
2016;388:2115-2127.30341730083346899129141175209243255289320347377398428459488520526
52.21381830085367187
FitzGerald22401830083324770100146181203236251290
JM,25441830083257993
Bleecker26511830083365186122154184219240
ER,29051830083336882
Nair30021830083447792113
P,312918300833540
et318318300833457
al.32541830083324760
Benralizumab,332918300833570108129162178193222260318350389401
an374518300833270
anti-interleukin-521381930083316889104125141178199231252267301338367383420442475
receptor26251930083205385118156178214235
α2872193008336
monoclonal292019300835794132169201216253290322336
antibody,32681930083326990104142180219250259
as353919300833257
add-on360819300833270108130168206
treatment21382030083214275107128185219256277
for24272030083185576
patients25152030083397192107141178199226
with27532030083506587124
severe,28892030083266092125146179191
uncontrolled,309220300833774105141179200221257272287321360372
eosinophilic34762030083347298112149186225263277292307338
asthma21382130083315780117174206
(CALIMA):23562130083195799130145199240259270
a2639213008331
randomised,26822130083215390129166224238264298337349
double-blind,304321300833876113151167201224263278293330368381
placebo-controlled343621300833854851171501882262492823183562138223008322438096111146186
phase233922300833977109136171
32525223008335
trial.2575223008321435991106119
Lancet.270922300833265103135169191204
2016;388:2128-2141.292922300833468100131143178213248260296327357391413444476507537546
53.21382330085367186
Goldman22442330083448298137195227265
M,252923300835568
Hirsch26172330083446081108140178
I,281523300831528
Zangrilli286323300833770108147168184199214229
JG,31122330083246982
et321423300833457
al.32912330083314760
The337123300833271106
association34972330083325985124156171203225240278317
between21382430083397496150184219258
blood24132430083395593131171
eosinophil260124300833473100115153191230269284299
count291824300833168106144166
and310124300833270109
benralizumab322724300833975113134167182197226264322355394
efficacy3638243008334537188121153213825300833165
for22192530083195678
patients23132530083397294109144182203231
with25612530083506688126
severe,27042530083266193128149183195
uncontrolled291625300833775107144182204225262278293328368
asthma:33002530083325982120178210222
subanalyses35392530083266310213517320622125321382630083266188
of224326300833756
the23162630083226095
Phase242826300833572105131166
III26112630083153045
SIROCCO26732630083334783131172211256
and294626300833270109
CALIMA307126300834083115130185227
studies.33152630083264987126142176203217
Curr35482630083407798120
Med368526300835489129
Res21382730083357097
Opin.225127300834686102140153
2017;33:1605-1613.241927300833468100130139174207219249280315349371402433464493506
54.21382830085367489
FitzGerald22492830083334871102148184206239255294
JM,25642830083248094
Bleecker26792830083355187123156186221242
ER,29422830083336983
Menzies-Gow304628300835591129159175210238259306345397
A,346428300834156
et354128300833456
al.36182830083324861
Predictors3700283008336579121382930083385283107143164191
of234129300833755
enhanced240929300833370108139176208241280
response27012930083205380118156193219253
with29672930083496586124
benralizumab310329300833873110131163178192221258315347385
for35002930083185576
patients35882930083387192107141178199226
with21383030083506688126
severe22763030083266193127148182
asthma:24703030083325881119176208220
pooled270330300833877115131166205
analysis292030300833270102117148175190216
of314830300833756
the32173030083215994
SIROCCO33243030083324682129170208253
and359030300833169108
CALIMA371030300834082213831300833147102144
studies.22973130083264987126141176203217
Lancet252931300833165103135169191
Respir27353130083367197136152173
Med.292331300835590129142
2018;6:51-64.308131300833468100131143179191227258276314350363
55.21383230085356983
Bleecker22343230083355084119150180213234
ER,24803230083326680
Wechsler257232300835789121158183198232253
ME,28373230083538698
FitzGerald2948323008331466898142177197229244282
JM,32423230083247891
et334532300833355
al.34123230083324659
Baseline34833230083356793127142156193227
patient37233230083387021383330083223772110131
factors22843330083185184108145166194
impact249233300831572112144177201
on270733300833876
the27973330083226095
clinical2907333008331466199114146179194
efficacy3116333008334527088120153185219
of334933300833757
benralizumab342033300833974112134166182197226264322354394
for21383430083185678
severe22313430083266193128149183
asthma.24293430083325982120178210223
Eur26683430083326990
Respir27733430083367197136152173
J.296134300832537
2018;52:1800936.301334300833469100131144179212224254285320357392425459472
56.21383530085367288
Nair22433530083457792113
P,237335300833539
Wenzel242835300835891129158193208
S,265235300833346
Rabe271435300833568107143
KF,28733530083356975
et296435300833456
al.30363530083324861
Oral311335300834769102117
Glucocorticoid-Sparing3246353008344609713016619923625828229833036638242144347451354621383630083213674113
Effect22663630083325170104137161
of244236300833756
Benralizumab251236300833671109130163179194223261319351390
in291736300831452
Severe29843630083326799134155189
Asthma.31873630083416992130188220234
N3435363008345
Engl349436300833371110125
J3633363008324
Med.367236300835489129142
2017;376:2448-2458.213837300833468100129139174206238251286318355391413444476509543556
57.21383830085367180
Pelaia22323830083356984116132164
C,240938300834053
Vatrella24753830083366789110144160175207
A,269638300834055
Bruni27643830083355795133148
A,292538300834155
et299438300833456
al.30633830083324861
Benralizumab313738300833570109130163178193222260318350390
in354038300831553
the36063830083226095
treatment37143830083224377213839300833254112147185206
of236039300833756
severe24323930083266193127149183
asthma:26303930083325882120177210222
Design,286739300834681108123162200212
development309539300833873105139155193233291326364385
and349639300833270109
potential3620393008339781001331712138403008322376984
place22384030083385486119152
in240640300831452
therapy.24734030083226095116149189220230
Drug271840300834667106145
Des287840300834581107
Devel300140300834580113147162
Ther.317940300833272107128138
2018;12:619-628.333340300833468100131143173203215251281311335372405439453
58.21384130085367288
Busse224641300833573100126161
WW,2426413008358119128
Bleecker25744130083355186121154184218239
ER,28324130083336982
FitzGerald29344130083324770100146181203236251290
JM,32434130083247993
et335541300833456
al.34314130083314760
Long-term351041300833169107146169191225246304
safety21384230083265978113135169
and232242300833270109
efficacy2447423008334527088120153185218
of268142300833757
benralizumab275342300833974112134167182197226264322354394
in316242300831553
patients32304230083397294109144182203231
with34774230083506688126
severe,36194230083266193128149183195
uncontrolled213843300833775107144183204226263279294329368
asthma:25234330083315881119177209222
1-year27614330083345385119151172
results29494330083215582119135157185
from31504330083184078136
the33024330083226095
BORA341343300833684120163
phase359243300833977110136171
33780433008334
extension21384430083346590124162188203241279
trial.2433443008321435890106119
Lancet256744300833165103135169191
Respir27734430083367197136152173
Med.296144300835590129143
2019;7:46-59.311944300833468100130143176186220256280314346357
59.21384530085367184
Bourdin223845300833574112133171186224
A,247845300834155
Chupp254845300834078116155194
G,275845300834357
Jackson28304530083255789119148186225
DJ,30704530083456880
et316545300833456
al.32374530083324760
MELTEMI331245300835588120149183238254
and358145300833270109
COLUMBA:370545300834086213846300833174128164205218
5-Year23694630083345689120151172
Comparative255446300834077135174207228261282297330364
Safety29314630083326584118140174
Analysis311846300834179111126158185199225
of335646300833757
Benralizumab342546300833671109130163178193222260317350389
and213847300833168106
Mepolizumab.225647300835488126164179193221259315347385397
J2665473008323
Allergy27004730083415570104124161192
Clin29044730083395468105
Immunol302147300831571128164201238254
Pract.32874730083345486117141153
2024;12:20742083.e4.34524730083346799130141170199211245278310340213848300833468104138150185221234
60.21384930085367388
Mattioli223949300835486108132147185200215
I,246749300831427
Urban250749300834364103136174
ML,269349300835486100
Padoan280549300833567105143176214
R,303149300833649
et309349300833456
al.31614930083324760
Mepolizumab323449300835489127166182196225263320353391
versus36384930083326686113150176
benralizumab213850300833974112133166182197226264322354393
for25475030083185677
eosinophilic263950300833473100115152191230269284299314346
granulomatosis30005030083385992130168183221280312334371397412438
with34535030083516789127
polyangiitis359550300833978941251581962138513008338536891106132
(EGPA):22855130083195196131169188200
A2499513008341
European25555130083336990128167203235273
real-life28435130083205486102124140155174209
retrospective3067513008320547798135162201237269293309341375
comparative345751300833268127166199220253275290323357
study.21385230083264987126158168
J2322523008324
Autoimmun.236152300834178101138153211269306344357
2025;153:103398.273452300833468101136146177207240251281312345378412447460
61.21385330085366981
Wenzel223653300835791129158192208
S,246053300833245
Ford25215330083327091130
L,266753300833145
Pearlman272853300833568100121137195227265
D,300953300834656
et308253300833456
al.31545330083324760
Dupilumab323053300834584123138154191249281321
in356753300831452
Persistent3635533008335699011713215821385430083225593115
Asthma22705430083416992130188220
with25075430083516689127
Elevated26515430083324782115147169203242
Eosinophil29105430083337097112150188228266281296
Levels.32235430083326698132148174188
N3427543008345
Engl348954300833370109125
J3631543008324
Med.367254300835489129142
2013;368:2455-2466.213855300833468100130141176211246259294326358391413444476512547561
62.21385630085367187
Rabe224656300833568107143
KF,24095630083356975
Nair25045630083447792113
P,263756300833539
Brusselle26965630083365795122148183199214249
G,296556300834357
et304256300833456
al.31185630083324760
Efficacy3198563008333516886118151183217
and343556300833270109
Safety35645630083326584118141174
of375856300833857
Dupilumab213857300834584123138153191249281320
in247157300831553
Glucocorticoid-Dependent25375730083435997129166198235257281297329366381420442489524564599637676711749771
Severe33215730083326799134155189
Asthma.35235730083416992130188220233
N3769573008345
Engl213858300833370109125
J2278583008324
Med.231858300835489129142
2018;378:2475-2485.247558300833468100131143178210244256291323355388410441473509543555
63.21385930085367287
Castro22445930083407399122144181
M,244459300835568
Corren25315930083407799120155193
J,274359300832436
Pavord27985930083356799136158196
ID,30135930083156071
et310359300833457
al.31795930083314760
Dupilumab325859300834583123138153191249281320
Efficacy3597593008333516986119151184217
and213860300833270109
Safety22666030083336684119141175
in246060300831553
Moderate-to-Severe253260300835493132167188221243277300322359383414449481516537571
Uncontrolled312260300834482114151189211232270285301335375
Asthma.35166030083416992130188220234
N3769603008345
Engl213861300833370109125
J2278613008324
Med.231861300835489129142
2018;378:2486-2496.247561300833468100131143178210244256291323359394418449481514549563
64.21386230085367489
Wenzel224862300835791129158192208
S,247662300833245
Castro25416230083407399122144181
M,274262300835568
Corren28306230083407799120154192
J,304262300832537
et309962300833456
al.31756230083324760
Dupilumab325562300834584123138154191249281321
efficacy3596623008333527088120153185218
and213863300833271111
safety22716330083266080115138173
in246563300831554
adults254063300833272111127150178
with27406330083516790129
uncontrolled289163300833877110147187209231269286301337378
persistent32906330083397698126141168192226265288
asthma35996330083326083123182215
despite213864300833975102143159182217
use237664300833865101
of249864300833858
medium-to-high-dose257864300835894135151189249272295333357397413453492515557596624660
inhaled32596430083155493126142178219
corticosteroids3499643008332709211813416620423225629121386530083215873112138
plus22896530083395593119
a2421653008332
long-acting24666530083145391130152185217241256294333
β2agonist:281265300833872104143181219234261284297
a3122653008332
randomised31676530083215492131169227242268303343
double-blind35236530083387611415316920422726721386630083153068107
placebo-controlled22586630083385487119152192230254287324363384406443459474509548
pivotal28196630083395587125147179195
phase302766300833977109136171
2b321166300833473
dose-ranging329766300833876103138161183216254293308346385
trial.3695663008321435990106119
Lancet.213867300833165103135169191204
2016;388:31-44.235867300833468100131143178213248260295326345382419431
65.21386830085367286
Weinstein224368300835791106144170193227242280
SF,25416830083336571
Katial26306830083356890105137153
R,280168300833549
Jayawardena28686830083245787120171204225263298336369
S,325568300833245
et331868300833456
al.33936830083314760
Efficacy3471683008332506886118151183217
and370668300833170109
safety21386930083265978113135169
of232069300833757
dupilumab239069300833876115131146183241273313
in271669300831553
perennial27826930083397496130168206221253268
allergic3064693008332476297118156171203
rhinitis32816930083205974112127149165191
and348569300833270109
comorbid36086930083316812616418621387030083395493
asthma.22467030083325982120178210224
J2485703008324
Allergy25247030083415772107128166198
Clin27377030083405670108
Immunol.286170300831472130168206244260273
2018;142:171-177.314970300833468100131143174205237250280309341360391420455461
66.21387130085367389
Simpson224571300833247105144171209248
EL,25107130083326478
Bieber26057130083355185124160181
T,280471300833241
Guttman-Yassky286271300834482105129187220258280313342369395425459
E,333971300833245
et340271300833456
al.34757130083324760
Two355371300833279117
Phase368771300833573105213872300832661
32212723008334
Trials2259723008333506597113139
of241172300833756
Dupilumab248072300834684123138154191249281320
versus28137230083326687115152178
Placebo30047230083355082114148187226
in324372300831452
Atopic33087230083416299139154186
Dermatitis.350772300834681102160193214230252267293307
N393463008345
Engl39946300833370109125
J413463008324
Med.41746300835489129142
2016;375:2335-2348.43316300833468100131144179211243254289324357390412443478513549563
67.3934730085367179
Blauvelt4027730083355183121153188203226
A,42667300834055
de43347300833872
Bruin-Weller4419730083365795110148171228262277292327348
M,47807300835568
Gooderham48617300834482121161196217255287345
M,52197300835568
et53007300833456
al.5369730083324760
Long-54427300833269107146168
-term393483008321437697155
management41018300835789127159197232289324361383
of44968300833756
moderate-to-severe45658300835795134168189222243276299321358381407442474508528562
atopic5140830083315389128144175
dermatitis5328830083377293151183204219241256282
with3934930083506688126
dupilumab40729300833875114129144182239271310
and43959300833169108
concomitant45159300833168106138174232247269302339361
topical4888930083225898113145177192
corticosteroids5093930083316889113128160197223246279300337352391417
(LIBERTY5522930083195065393410300833568103136175
AD412110300834186
CHRONOS):422010300834083119166211259291309321
a4554103008331
1-year,45981030083345283117149170179
randomised,47901030083205390129167224239265299338351
double-blinded,515310300833876114152168202225265280295332371405444457
placebo-controlled,39341130083385485117150188226249282318356377398435450465499538550
phase449611300833976108134168
34677113008333
trial.4723113008321425789103116
Lancet.485111300833164101133166188201
2017;389:2287-2303.50641130083346798127136171205238251285319353385403433467501534546
68.39341230085367491
Busse404612300833674101128164
WW,4231123008358119129
Maspero438112300835588116155191213251
JF,46531230083245864
Rabe473812300833669109145
KF,49041230083357076
et500112300833457
al.50791230083324861
Liberty51611230083324887124145170205
Asthma53871230083416993132190223
QUEST:393413300834791125158193201
Phase415513300833573105132167
34342133008334
Randomized,439613300833568106145183242257286320360372
Double-Blind,478813300834684122162177212235273288303341380393
Placebo-Controlled,520113300833550821141481872262492923293683893934143008321587489123163175
Parallel-Group41221430083366788121137152186202224270292329367406
Study45411430083335491130162
to471614300832259
Evaluate47881430083326497112149182203237
Dupilumab503814300834583122138153190248280320
Efficacy/5371143008332506885117150182216239
Safety39341530083326583117139172
in411815300831552
Patients41831530083346687102136174195222
with44171530083506587125
Uncontrolled,455515300834380112148186207228265280295329368380
Moderate-to-Severe494815300835491130165185218239272295317353376407441473507528561
Asthma.552215300834067393416300832260118150163
Adv411316300834179112
Ther.424016300833272107128138
2018;35:737-748.439416300833468100131143178211222255289321340371402438451
69.39341730085367285
Bachert403417300833568101139173195219
C,426817300834053
Han433517300834577115
JK,44641730083256075
Desrosiers455317300834681108129166193208242264291
M,485817300835568
et494117300833456
al.50121730083324760
Efficacy5086173008333516986119151184217
and531817300833270109
safety54411730083265978113135169
of393418300833757
dupilumab400918300833876115130145183241273312
in434018300831452
patients44111830083387193108143181203230
with46601830083506688126
severe48051830083266193127149183
chronic50061830083316990128166181213
rhinosinusitis52371830083216075112151177192230268294309331347373
with39341930083516689127
nasal40781930083377096129145
polyps42401930083387793125165191
(LIBERTY44481930083195066102135170204243
NP470819300834581
SINUS-2448061930083324792136168190221253
and507619300833270109
LIBERTY52021930083314782116151185224
NP544319300834580
SINUS-52):554019300833347393420300834589121143177210228240
results41872030083215582119135157185
from43852030083184078136
two453420300832275112
multicentre,466020300835795110132148180213251273294328340
randomised,50142030083205391130168227242268303343355
double-538220300833877115154170205228
-blind,3934213008321607690128166179
placebo-controlled,41252130083385486118151189228251284320358379400437453468502541553
parallel-group46912130083387191124139154188203225265286323360399
phase510321300833876108134168
35284213008334
trials.5330213008322435890105130143
Lancet.54862130083316410239342230083316587101
2019;394:1638-1650.405022300833468100130143178211247259289320354388411442473507541553
70.39342330085377389
Yosipovitch40452330083367199115155195228245268300339
G,440623300834459
Mollanazar448623300835696112128161201234265299321
N,482923300834659
Ständer49102330083335589128169205227
S,515823300833447
et522723300833458
al.53062330083334962
Dupilumab539023300834686126143159197393424300835891131
in408624300831554
patients41612430083397395111146185207236
with44182430083516790129
prurigo456824300833961100122138178217
nodularis:480624300833877117156171204226242269282
two510924300832276114
randomized,52442430083215594134173232247277312352365
double-blind,393425300833877116156172207231271287303341381394
placebo-controlled43492530083395588120154194234257291329368390412449466481516556
phase492625300833978111138174
35121253008334
trials.5176253008322446092108134148
Nat534525300834578100
Med.546625300835590131144
2023;29:1180-1190.393426300833468101136147182216229259287318353377408436466502514
71.39342730085367183
Dellon40342730083458196111149188
ES,42382730083336780
Rothenberg43342730083357496134169207246282303341
ME,469127300835588101
Collins48092730083407792108123160187
MH,501227300835599112
et514127300833456
al.52132730083324861
Dupilumab529027300834584123138154191249281320
in393428300831553
Adults400528300834179117132154182
and420628300833169108
Adolescents433328300834179117133168195227261299320348
with47002830083506688126
Eosinophilic48452830083327096111149187227266281296311343
Esophagitis.52062830083336099138177209248263286301327341
N5565283008345
Engl393429300833370109125
J4074293008324
Med.411429300835489129142
2022;387:2317-2330.427129300833468101136148183218251261296331362391410441475508543555
72.39343030085367288
Gauvreau403830300834476114147169203234272
GM,432630300834398112
O’Byrne44543030083476096128150189224
PM,469430300833588102
Boulet481230300833573112127162184
L-P,5012303008331468388
et511530300833457
al.51873030083324860
Effects52633030083335271105138162190
of546830300833857
an554130300833169
Anti-TSLP393431300834178100115136166199230265
Antibody42123130083407899114153191231262
on448731300833775
Allergen-Induced45743130083415671105126164198236258274312350388419453492
Asthmatic50783130083416891129186218240255286
Responses.5377313008335699613417321139343230083266188102
N4051323008345
Engl411132300833270109125
J4251323008324
Med.429032300835590129143
2014;370:2102-2110.444832300833468100131143178210243256291323354387407438470497529541
73.39343330085367287
Takai40423330083336191124139
T.420233300833242
TSLP42643330083336697133
Expression:441733300833366105127161188214229267306318
Cellular47553330083407489105142157190211
Sources,498633300833371109130161195222235
Triggers,52413330083335066105144179200227240
and550133300833270109
Regulatory393434300833570110148163195217254275309
Mechanisms.425934300835489122160192230245271329355369
Allergol46433430083415772107128166204220
Int.4878343008315537588
2012;61:3-17.498134300833569100130143178209217252274305335341
74.39343530085366884
Dahlén403435300834578116131166204
S-E.42543530083335590103
TSLP43743530083326697132
in452335300831553
Asthma45923530083416992130188220
—4829353008370
A4916353008340
New497335300834580131
Kid51203530083355291
on522735300833776
the53193530083226095
Block?54313530083355189122152179
N3934363008345
Engl399436300833370109125
J4134363008324
Med.417436300835489129142
2014;370(22):2144-2445.433136300833468100131143178210243263297331349361396428459496519550582619651663
75.39343730085367085
Menzies-Gow403437300835490128157173207234255302340391
A,444137300834155
Corren45113730083407798120154192
J,471837300832436
Bourdin477037300833573111133171186224
A,500937300834155
et507937300833456
al.51503730083324861
Tezepelumab52263730083326393127166201217254312345384
in393438300831451
Adults399838300834077114129151178
and418838300833168106
Adolescents430738300834077115130164190222255292313340
with46593830083506586124
Severe,47953830083326698131152185196
Uncontrolled500338300834481112148186206227264279294328366
Asthma.53813830083416890128184216229
N3934393008345
Engl399439300833370109125
J4134393008324
Med.417439300835489129142
2021;384:1800-1809.433139300833468101133141176210247259289320355391415446477512547558
76.39344030085367086
Wechsler403440300835791123161188203238259
ME,430740300835588101
Colice44224030083407793108140174
G,461040300834457
Griffiths4682403008343658199117135157195222
JM,49184030083247993
et502540300833456
al.50964030083314760
SOURCE:517040300833280125160201234247
a5432403008331
phase547840300833877109393441300832661
3,401141300833446
multicentre,407341300835794110132147179213251273294328340
randomized,44294130083205391130169227242271305345357
double-blind,480241300833876114154169204227267283298336375388
placebo-controlled,520541300833955871191531922312552883253643853934423008321587489124163176
parallel41274230083397293126142157191207
group43524230083385996134173
trial4543423008321435890106
to466642300832259
evaluate47424230083346699115152184206240
the49994230083226095
efficacy5112423008334527088120153185218
and534842300833270109
safety54744230083265978113393443300832257
of401343300833858
tezepelumab40934330083225788123164201217256316349390
in450543300831554
reducing45804330083225798137170186225266
oral48674330083396195112
corticosteroid50004330083327193119135168206234258293316354370411
use543243300833866102
in555643300831554
adults393444300833272110126149177
with41324430083526891130
oral42834430083386093109
corticosteroid44134430083327092117133165203230254288310348364404
dependent483844300833874114150189229265303325
asthma.51844430083336084123181214228
Respir54334430083367299139155177
Res.39344530083357097111
2020;21:1-10.406045300833468101135148183215223253272302334346
77.39344630085367281
Wechsler402846300835790123160186201236257
ME,429846300835487100
Menzies-Gow441146300835489127156171206232253299338388
A,481246300834155
Brightling48804630083355671110148169184199237275
CE,51684630083407285
et526646300833456
al.53354630083314759
Evaluation5407463008333649711214918139344730083223774113
of405947300833757
the41284730083226095
oral42354730083375992107
corticosteroid-sparing43554730083316789113128160197223246279301338353391413440479512533548586624
effect49924730083345372106139163
of516747300833857
tezepelumab52364730083225585119158193208246303335374
in393448300831552
adults399948300833271108123145173
with41854830083506588126
oral43234830083385992107
corticosteroid-dependent44434830083316889113129160197224246280301338353392414454489528563601640675712734
asthma51904830083315881119176208
(SOURCE):5411483008319509714217739344930083397291103
a4049493008331
randomised,40934930083205390128166223238264298337349
placebo-controlled,44544930083395486117150189227250283319357378399436451466500539551
phase501849300833876108134168
35198493008334
study.52444930083264986125156166
Lancet542249300833164101133166188
Respir39345030083357097136152173
Med.412250300835590129142
2022;10:650-660.428050300833468101136148178209223258292326350387423458471
78.39345130085367187
Jackson40375130083245688119147186224
DJ,42775130083456779
Lugogo437251300833269108146185224
NL,46115130083457790
Gurnell471751300834482103142177192207
M,494051300835568
et502451300833456
al.50965130083314760
Oral517151300834769102118
corticosteroid5304513008331689011513016219922524928239345230083215873112
reduction40655230083205594132164188203241280
and436352300833270109
discontinuation44915230083385379111148187208224261299331353368406445
in495452300831553
adults502652300833171108123146173
with52185230083516689127
corticosteroid-dependent,5364523008331688911412916119822539345330083215576113128166188228263302337375413448486507520
severe,44675330083266092126147181192
uncontrolled467253300833775106143181202224260276291325365
asthma50495330083325881119176208
treated52705330083214276108129162202
with54845330083516688126
tezepelumab39345430083225584118157193208245303335374
(WAYFINDER):432154300831878116147181195240285319354373384
a4718543008332
multicentre,476354300835794109131147178212250271292326338
single-arm,51145430083264078117132166189222242301313
phase544054300833877109135170
3b393455300833473
trial.4022553008322435991106119
Lancet415655300833265103135169191
Respir43635530083357097136151172
Med.455155300835489129142
2026;14:129-140.470855300833569101135147177209221250280314338369400436448
79.39345630085367185
Menzies-Gow403956300835490128157173207234255302340391
A,445056300834155
Ponnarambil452456300833672111149181202235293332348363
S,490656300833346
Downie497156300834584135174189223
J,521456300832436
et526956300833457
al.53455630083324760
DESTINATION:542556300834578112147163393457300834586115131179225237
a4188573008332
phase423757300833978110136171
3,442657300833446
multicentre,448957300835795110133148180214252273295329341
randomized,48475730083215492131169227242271305345358
double-blind,522257300833876114153169204227267283298336375388
placebo-controlled,39345830083395587119153192231254288325363385406443459474509549561
parallel-group45115830083397293126142157191207229270291328366405
trial4932583008322445991107
to505558300832158
evaluate51295830083346699115152184206240
the53855830083226095
long-term5496583008315539139345930083386083117138196
safety41465930083266079113135169
and433159300833270109
tolerability44565930083225975110131164203219234249271305
of477759300833757
tezepelumab48505930083215585119158194209247304337376
in524259300831553
adults531159300833271108124146174
and550159300833270109
adolescents393460300833271110126161188221255293315343
with42986030083516789128
severe,44476030083266194128150184196
uncontrolled466460300833776108146184206228266282297332372
asthma.50576030083325982121179212225
Respir53036030083357198137153174
Res.54986030083357198112
2020;21:1-10.393461300833468101135148183214223253272302334346
80.39346230085367490
Kelsen40396230083357086113149187
SG,42426230083327791
Agache434962300834180113146184220
IO,45846230083156475
Soong467562300833271111150190
W,488062300835768
et496362300833457
al.50356230083324862
Astegolimab51126230083417093128168207224239298331371
(anti-ST2)549862300831950893934633008322396295131168187
efficacy4144633008335547291124159192227
and439463300833272113
safety45296330083276282118142177
in472963300831454
adults480663300833273112128152181
with50106330083516892132
severe51656330083266397132155191
asthma:53786330083336185125185219232
A3934643008341
randomized39986430083215594135174234250281316357
clinical43776430083324864103120153187203
trial.4603643008322446194111125
J4750643008324
Allergy47976430083415874110132172205
Clin50256430083405672112
Immunol.515964300831574134173212252269283
2021;546464300833470104137146
148:790-798.393465300833466103116150184220245277311346361
81.39346630085367184
Wechsler403966300835892125164191207242264
ME,432466300835589103
Ruddy444866300833574114153186
MK,465566300835591107
Pavord478366300833568100138160199
ID,50036630083156273
et509766300833457
al.51756630083324861
Efficacy5257663008333527088121154187221
and549966300833271111
Safety39346730083336685120143177
of413267300833857
Itepekimab42106730083153872112148179195254287326
in455767300831553
Patients46316730083366890106141180201230
with48816730083516790129
Moderate-to-Severe503167300835594134169191224246280304327364388420455488523544579
Asthma.39346830083416992130188220234
N4183683008345
Engl424368300833370109125
J4383683008324
Med.442268300835590130143
2021;385:1656-1668.458068300833468101133141176210244255285316350384408438470505541554
82.39346930085367288
Corren40376930083407798120154192
J,424469300832537
Reid42966930083357085124
F,443569300833238
Moate448869300835593126148181
R,468469300833650
et474969300833456
al.48206930083324760
S90489569300833265101
FRONTIER-3:501169300833267115161195211244280302334345
a5371693008332
randomized,54186930083215492131169393470300835772102136175188
phase413670300833978110137172
2a432270300833467
study44037030083264987126158
to457670300832259
evaluate46497030083346699115152185206240
the49047030083216095
efficacy5013703008334537088120153185219
and524670300833270109
safety53707030083265978113135169
of555370300833757
tozorakimab39347130083215886123144176206222279311350
(an42977130083184886
anti-interleukin-3343957130083327091106128143181202235256272306344373389427449481513
monoclonal492171300835795133171203218256294326341
antibody)52747130083326991106144183222253271
in555871300831452
early-onset39347230083346687103135157196235261296318
asthma.42687230083315881119177209223
Thorax.450672300833372110132165196210
2024;79:A65-A66.473172300833569102133145178212225267301335357398432468481